Literature DB >> 11420464

TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma.

S C Peh1, L H Kim, S Poppema.   

Abstract

Thymus and activation-regulated chemokine (TARC) has been identified as a lymphocyte-directed CC chemokine that attracts activated T-helper type 2 (Th2) cells in humans. Recent studies showed that the T cells surrounding Reed-Sternberg cells in Hodgkin's lymphomas (HL) are Th2 type. Anaplastic large cell lymphomas (ALCL), T-cell-rich B-cell lymphoma (TCRBCL) can mimic HL in some instances. This study aimed to establish the pattern of TARC expression in these diseases. Immunohistochemical stain using a polyclonal goat anti-human antibody to TARC was performed on 119 cases of confirmed HL; 99 were classical type (43 mixed cellularity, 43 nodular sclerosis, 5 lymphocyte depleted, 4 lymphocyte rich, 4 unclassifiable) and 20 lymphocyte predominant HL. Additional 27 ALCL (9 T-, 18 null-cell phenotype), 16 T-cell and 8 B-cell non-Hodgkin's lymphoma (NHL) were studied. A total of 85.8% of the classical HL, one case of ALCL, and one case of large cell B-cell lymphoma with anaplastic morphology showed positive TARC expression in the tumor cells. The expression was paranuclear and/or diffuse in the cell cytoplasm. The tumor cells in all cases of lymphocyte predominant HL, TCRBCL, null ALCL, and T-NHL did not express TARC. The high frequency of TARC expression in the Reed-Sternberg cells of classical HL may explain the characteristic T-cell infiltrate in this disease. The absence in other types that may be morphologically similar indicates that staining for TARC may aid in differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420464     DOI: 10.1097/00000478-200107000-00011

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

Review 1.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

2.  HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.

Authors:  Emilie Lanoy; Philip S Rosenberg; Fabien Fily; Anne-Sophie Lascaux; Valerie Martinez; Maria Partisani; Isabelle Poizot-Martin; Elisabeth Rouveix; Eric A Engels; Dominique Costagliola; James J Goedert
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

Review 3.  Hodgkin's lymphoma therapy: past, present, and future.

Authors:  Bharti Rathore; Marshall E Kadin
Journal:  Expert Opin Pharmacother       Date:  2010-12       Impact factor: 3.889

4.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.

Authors:  Wouter J Plattel; Anke van den Berg; Lydia Visser; Anne-Marijn van der Graaf; Jan Pruim; Hans Vos; Bouke Hepkema; Arjan Diepstra; Gustaaf W van Imhoff
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.

Authors:  Jianhua Zhou; Ning Kang; Lianxian Cui; Denian Ba; Wei He
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

6.  The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.

Authors:  Daniela Buglio; Vidya Mamidipudi; Noor M Khaskhely; Helen Brady; Carla Heise; Jeffrey Besterman; Robert E Martell; Kyle MacBeth; Anas Younes
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

Review 7.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

8.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

9.  Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin.

Authors:  Michelle Furtado; Simon Rule
Journal:  Clin Med Insights Oncol       Date:  2012-01-04

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.